Equities research analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to report earnings of ($0.33) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Axsome Therapeutics’ earnings. Axsome Therapeutics reported earnings per share of ($0.27) in the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 14th.

On average, analysts expect that Axsome Therapeutics will report full-year earnings of ($1.15) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($1.12). For the next financial year, analysts expect that the firm will post earnings of ($0.70) per share, with EPS estimates ranging from ($1.15) to ($0.25). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Axsome Therapeutics.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32).

A number of equities research analysts have issued reports on AXSM shares. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 26th. HC Wainwright started coverage on shares of Axsome Therapeutics in a report on Thursday, June 7th. They set a “buy” rating and a $10.00 price target for the company. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Axsome Therapeutics currently has an average rating of “Buy” and a consensus price target of $11.38.

NASDAQ:AXSM traded down $0.02 during trading hours on Friday, reaching $3.40. The company’s stock had a trading volume of 1,351 shares, compared to its average volume of 126,583. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.74. Axsome Therapeutics has a one year low of $2.05 and a one year high of $6.45. The stock has a market capitalization of $89.26 million, a PE ratio of -2.74 and a beta of -0.15.

In other news, CFO Nick Pizzie purchased 31,000 shares of the firm’s stock in a transaction on Tuesday, June 19th. The stock was bought at an average cost of $3.10 per share, for a total transaction of $96,100.00. Following the completion of the acquisition, the chief financial officer now directly owns 400 shares of the company’s stock, valued at $1,240. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 34.30% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC bought a new stake in Axsome Therapeutics during the first quarter valued at about $145,000. Sabby Management LLC bought a new stake in Axsome Therapeutics during the first quarter valued at about $199,000. Sio Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the first quarter valued at about $474,000. Renaissance Technologies LLC acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $271,000. Finally, Alethea Capital Management LLC raised its position in shares of Axsome Therapeutics by 132.5% during the second quarter. Alethea Capital Management LLC now owns 270,823 shares of the company’s stock valued at $867,000 after buying an additional 154,323 shares during the last quarter. Institutional investors own 15.62% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.